Legal Information
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Luminex is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 7 analytes in human serum, plasma, and cell culture supernatants.Analytes included: Granzyme B, HSP70, IL-1α, IL-8, MIP-1α, MIP-1β, MMP-8Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Features and Benefits
Immune Response Research Panel: Luminex® xMAP® platform simultaneously quantitates 7 critical immune response biomarkers (Granzyme B, HSP70, IL-1α, IL-8/CXCL8, MIP-1α/CCL3, MIP-1β/CCL4, MMP-8) for comprehensive sepsis immunology research. Streamlined Sample Processing: Compatible with human serum, plasma, and cell/tissue culture supernatants using neat sample analysis - no dilution required, simplifying research protocols and minimizing sample handling errors.Multi-Pathway Sepsis Research: Investigate cytotoxic T-cell responses (Granzyme B), cellular stress (HSP70), pro-inflammatory cytokines (IL-1α, IL-8), chemokine signaling (MIP-1α, MIP-1β), and tissue remodeling (MMP-8) in sepsis pathogenesis studies.Comprehensive Immune Profiling: Simultaneously measure innate immune activation, adaptive immune responses, chemotactic signals, and tissue damage markers to understand complex sepsis immunopathology in research settings.Translational Sepsis Research: Address critical research gaps in understanding sepsis progression from initial immune response through SIRS, severe sepsis, and potential progression to MODS in experimental studies.Flexible Research Applications: Configure analyte selection for specific research questions and adapt to various experimental designs from mechanistic cell culture studies to clinical research sample analysis.
General description
Sepsis or SIRS (systemic inflammatory response syndrome) results from infection, whether bacterial, viral, fungal, or parasitic. The pathogenesis of sepsis is very complex. Both an innate and acquired immune response to infection interrupts homeostasis with a shift of cytokine expression that increases immunosuppression. In addition, migration of the leukocytes in the inflamed tissues secretes a tissue factor leading to the formation of thrombin, also triggering the release of chemokines and adhesion molecules through endothelial cells. Severe sepsis occurs when hypotension or hypoperfusion to one or more organs leads to organ dysfunction, which, in turn, can cause septic shock, multiple organ dysfunction syndrome (MODS) and death.
